Clinical trial
Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an…
NCT00321763 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00321763 |
|---|---|
| Title | Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate |
| Official title | Demonstrate the Lot-to-lot Consistency of 3 Consecutive Production Lots of an Adjuvanted Influenza Vaccine Candidate and Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate Versus Fluarix™ Administered Intramuscularly in Elderly |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Candidate Influenza Vaccine GSK1247446A - 3 different formulations, Fluarix TM |
| Enrollment | 3,124 |
| Start date | Apr 27, 2006 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 7, 2006 |
| First posted | May 4, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | Estonia, France, Germany, Greece, Norway, Russia, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: